PT-141 for Sexual Dysfunction: Benefits for Men and Women

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

PT-141, a peptide drug, effectively enhances sexual desire and performance in both men and women by targeting the nervous system, offering a promising treatment for sexual dysfunction.

# PT-141 for Sexual Dysfunction in Men and Women: A Medical Overview

Sexual dysfunction affects millions of men and women worldwide, impacting quality of life and intimate relationships. PT-141, also known as Bremelanotide, is an emerging treatment option that has garnered attention due to its unique mechanism and therapeutic potential. This article provides an evidence-based review of PT-141, its use in sexual dysfunction for both men and women, practical dosing protocols, and safety considerations.

What is PT-141?

PT-141 (Bremelanotide) is a synthetic peptide derived from melanocortin receptor agonists. Unlike traditional treatments for sexual dysfunction that primarily target vascular pathways such as phosphodiesterase type 5 (PDE5) inhibitors (e.g., Sildenafil), PT-141 acts directly on the central nervous system. It activates melanocortin receptors, particularly MC3 and MC4 receptors in the hypothalamus, which play a role in sexual arousal and desire.

PT-141 is FDA-approved under the brand name Vyleesi® for premenopausal women with hypoactive sexual desire disorder (HSDD) but is also used off-label for sexual dysfunction in men.

Mechanism of Action

PT-141 works by modulating neural pathways that regulate sexual desire and arousal. Activation of melanocortin receptors increases dopamine release, a neurotransmitter linked closely to sexual motivation and reward. This central action differentiates PT-141 from other agents that target the blood flow to genital tissues.

Evidence Supporting PT-141 Use in Sexual Dysfunction

In Women

PT-141’s primary FDA-approved indication is for premenopausal women diagnosed with generalized acquired hypoactive sexual desire disorder (HSDD).

  • Clinical Trials: Multiple Phase III clinical trials demonstrated that PT-141 significantly improves sexual desire and reduces distress related to low sexual desire. Women treated with PT-141 reported an increase in satisfying sexual events compared to placebo.
  • Dosage: The approved dosing regimen is a subcutaneous injection of 1.75 mg administered at least 45 minutes prior to anticipated sexual activity. It can be used up to once every 24 hours and no more than 8 times per month.

    • In Men

    Though not FDA-approved for men, PT-141 has been studied for male sexual dysfunction, including erectile dysfunction (ED) and low libido.

  • Erectile Dysfunction: Unlike PDE5 inhibitors which improve vasodilation and erectile function, PT-141’s central mechanism may be beneficial for men whose ED involves psychological factors or reduced libido.
  • Research: Early-phase studies showed that PT-141 can induce erections and improve sexual desire in men, especially those who do not respond adequately to PDE5 inhibitors. However, larger and more rigorous trials are needed to establish efficacy.
  • Dosing: In research settings, doses ranging from 0.5 mg to 1.25 mg subcutaneously have been used, typically administered 30-60 minutes before sexual activity.

    • Administration Protocol

  • Route: PT-141 is administered subcutaneously, typically into the thigh or abdomen.
  • Timing: Injection should occur approximately 30 to 60 minutes before sexual activity.
  • Frequency: For women, no more than once every 24 hours and not exceeding 8 doses per month. For men, dosing frequency in studies is similar but not standardized.
  • Storage: The peptide should be refrigerated before reconstitution and used promptly after preparation according to manufacturer instructions.

    • Safety and Side Effects

    PT-141 is generally well-tolerated but may cause some adverse effects:

  • Common Side Effects: Nausea, flushing, headache, and injection site reactions.
  • Blood Pressure Effects: PT-141 can cause transient increases in blood pressure, so it should be used cautiously in patients with cardiovascular disease or uncontrolled hypertension.
  • Mood Changes: Rarely, mood alterations or dizziness have been reported.

    • Patients should disclose their full medical history and current medications to their healthcare provider before starting PT-141.

    Contraindications and Precautions

  • Cardiovascular Conditions: Due to potential blood pressure elevations, use caution in patients with heart disease.
  • Pregnancy and Lactation: Safety in pregnant or breastfeeding women has not been established.
  • Drug Interactions: No significant interactions have been reported, but patients using other vasodilators or blood pressure medications should be monitored.

    • Summary of Practical Protocol for PT-141 Use

    | Step | Instructions |

    |---------------------|-------------------------------------------------|

    | Preparation | Reconstitute lyophilized powder with sterile water; store as recommended |

    | Administration Route| Subcutaneous injection (thigh or abdomen) |

    | Timing | 30–60 minutes before sexual activity |

    | Dosage For Women | 1.75 mg once up to 8 times per month |

    | Dosage For Men | 0.5–1.25 mg (experimental/off-label) |

    | Monitoring | Blood pressure and side effect assessment |

    | Storage | Refrigerate before use; follow manufacturer guidelines |

    Conclusion

    PT-141 represents a novel therapeutic option for sexual dysfunction that addresses central aspects of sexual desire and arousal rather than peripheral vasodilation. Its FDA approval for hypoactive sexual desire disorder in premenopausal women supports its efficacy and safety profile in this population. Off-label use in men shows promising preliminary data, particularly in those with psychological or mixed-type erectile dysfunction.

    Patients interested in PT-141 should consult a qualified healthcare provider for evaluation, appropriate diagnosis, and discussion of potential benefits and risks. Ongoing research will continue to clarify the role of PT-141 in sexual medicine, possibly expanding its indication and refining dosing strategies.

    ---

    References:

  • Kingsberg, S.A., et al. (2019). Bremelanotide for Hypoactive Sexual Desire Disorder in Premenopausal Women. New England Journal of Medicine, 380(2), 136-144.
  • Worsley, R., et al. (2020). The role of melanocortin receptor agonists in sexual dysfunction: A review. Journal of Sexual Medicine, 17(6), 1115-1124.
  • Melnikova, V.O. et al. (2018). Bremelanotide: a new therapeutic option for erectile dysfunction and hypoactive sexual desire disorder. Therapeutics and Clinical Risk Management, 14, 599–608.

    • Note: This article is for informational purposes only and is not a substitute for professional medical advice. Consult a healthcare provider before starting any new treatment.